Senores Pharmaceuticals Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/bqms29j27p765vyhbts75uu0.pdf

Key Takeaways


Revenue Bridge: The INR15 Crore Shift


Regulated Markets: ANDA Portfolio Build-Out

Shah: "So we literally handled our customer right from the product idea to launch of a product, So that's our USP. And being multi-geographically present, this really gives us an edge compared to all other competitors that exist in the marketplace."

Tariff & Supply-Chain Insulation

Majmudar: "I am a US company, manufacturing in US, buying in US, selling in US. So to that extent, it doesn't matter."

Emerging Markets: Margin Inflection Story


Capacity Expansion & Backward Integration


Margins & Profitability

Majmudar: "It will only improve. 100% sustainable."

Guidance & Commitments

CommitmentSpecificsTimeline
Top-line growthAt least 50%+ year-on-yearFY26 full year
PAT growthAt least 100% year-on-year (after minority interest)FY26 full year
EBITDA marginMaintain 24–26% rangeAnnual basis, FY26
ANDA launches31 products in regulated marketFY26
CDMO-CMO launches23 productsFY26
Acquired ANDA commercial launchesPhased launches of Dr. Reddy's portfolioBeginning Q3 FY26
Emerging market registrations650+ registered products across all emerging marketsBy end of FY27
Emerging market EBITDA marginMove close to double digits; 15–16% targetNext year; within two years
API facility US FDA triggerFile and trigger inspectionQ2 CY26
Injectable capexBegin investmentEnd of current year

Key Metrics

MetricQ4 FY25
Revenue₹410 cr (FY25), +91% YoY
Regulated market revenue₹64 cr, +17% YoY
Emerging market revenue₹37 cr
Consolidated EBITDA₹102 cr (FY25), +145% YoY
EBITDA margin25% (FY25), +540 bps YoY
Regulated market EBITDA marginupwards of 40%
Emerging market EBITDA margin7% (FY25)
Consolidated PAT after minority interest₹59 cr (FY25), +86% YoY
PAT growth guidance~100% (FY26), in absolute terms
Revenue growth guidanceat least 50% plus (FY26)
Revenue mix guidance~70% regulated, ~30% emerging, steady-state annualized
Commercialized ANDA portfolio22 as of March 31, 2025
Total ANDA portfolio61
CDMO-CMO portfolio22 products
CDMO-CMO pipeline69 products as of March 2025
Emerging market registered products285 as of March 31, 2025
Emerging market portfolio target650+ registered products by end FY27
Products expected to launch in FY2631 ANDA products in regulated market, 23 CDMO-CMO products
Revenue shifted from Q4 to Q1₹15 cr anticipated revenue not realized in Q4
Trade receivables days108 days, reduced from 228 days in FY24
Inventory days43 days, reduced from 69 days in FY24
R&D expenses₹3.5 cr total debited to P&L
Capex planned for FY26₹250 cr
Ratnatris Pharmaceuticals full-year revenue₹121 cr